KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Current Assets (2017 - 2026)

Moderna (MRNA) has disclosed Current Assets for 10 consecutive years, with $5.8 billion as the latest value for Q1 2026.

  • For Q1 2026, Current Assets fell 14.72% year-over-year to $5.8 billion; the TTM value through Mar 2026 reached $5.8 billion, down 14.72%, while the annual FY2025 figure was $6.5 billion, 19.2% down from the prior year.
  • Current Assets hit $5.8 billion in Q1 2026 for Moderna, down from $6.5 billion in the prior quarter.
  • Across five years, Current Assets topped out at $16.4 billion in Q1 2022 and bottomed at $5.8 billion in Q1 2026.
  • Average Current Assets over 5 years is $10.0 billion, with a median of $9.7 billion recorded in 2024.
  • Year-over-year, Current Assets soared 39.71% in 2022 and then crashed 36.12% in 2025.
  • Moderna's Current Assets stood at $13.4 billion in 2022, then fell by 23.13% to $10.3 billion in 2023, then dropped by 21.56% to $8.1 billion in 2024, then dropped by 19.2% to $6.5 billion in 2025, then decreased by 11.83% to $5.8 billion in 2026.
  • According to Business Quant data, Current Assets over the past three periods came in at $5.8 billion, $6.5 billion, and $6.6 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.